SNGX: Positive Results for Phase 2a Trial in Psoriasis

About this update from Soligenix, Inc.

[{"type":"text","content":"By David Bautz, PhD","length":19,"tagName":"p"},{"type":"text","content":"NASDAQ:SNGX","length":11,"tagName":"p"},{"type":"text","content":"READ THE FULL SNGX RESEARCH REPORT","length":34,"tagName":"p"},{"type":"text","content":"Business Update","length":15,"tagName":"p"},{"type":"text","content":"Positive Results for SGX302 in Cohort 3 of Phase 2a Psoriasis Trial","length":67,"tagName":"p"},{"type":"text","content":"On December 17, 2025, Soligenix, Inc. (NASDAQ:SNGX) announced positive results from Cohort 3 of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis. Cohort 3 consisted of four patients who were enrolled and treated with an improved topical gel formulation of synthetic hypericin. The gel formulation was designed to improve the patient experience as it is easier to dispense and apply to the skin. The patients were treated for 18 weeks, similar to patients in Cohort 1 and 2. For the three evaluable patients (one patient discontinued for personal reasons), noted improvements were seen in the Investigator Global Assessment (IGA), the Psoriasis Activity and Severity Index (PASI), the simplified psoriasis index, the dermatology life quality index and the Skindex-29 questionnaire. Importantly, one patient achieved a disease status of “Almost Clear” using the IGA and a >50% improvement in PASI score. Looking at the totality of the data generated in the Phase 2a trial thus far, its suggestive that SGX302 improves psoriatic lesions and is well tolerated.","length":1117,"tagName":"p"},{"type":"text","content":"The ongoing Phase 2a trial is a randomized, double blind, placebo controlled study this is enrolling patients with mild-to-moderate, stable psoriasis covering 2% to 30% of their body. In Cohort 1, five patients received twice weekly treatment for 18 weeks with 0.25% hypericin ointment followed by light activation approximately 24 hours later. Light doses were increased by up to 1 J/cm2 on subsequent visits until mild erythema was observed. A clear biological signal was observed in the initial five patients based on an improvement in the PASI, but no patient met the definition of treatment success (IGA score of 0 or 1). The second cohort of patients received an accelerated light treatment with increases in the light dose by up to 2 J/cm2 allowing the maximum dose (2...

More updates from Soligenix, Inc.